Wedbush initiated coverage on Prime Medicine with a new price target
$PRME
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wedbush initiated coverage of Prime Medicine with a rating of Outperform and set a new price target of $12.00